Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

New Report Shows Big Spike in Prescriptions for EpiPen Alternatives

By Ryan Bushey | March 8, 2017

The fallout from Mylan’s EpiPen pricing controversy appears to be taking a toll, according to a new analysis

Medical records and billing company Athenahealth published a report analyzing data from more than 1,400 medical providers showing prescriptions for alternatives to the brand-name allergy shot quadrupled in the beginning of the year.

Competing products like Kaleo’s Auvi-Q and CVS Health’s Adrenaclick accounted for only 5.3 percent of prescriptions for these devices in December 2016. Those numbers jumped to 14.8 in January and then reached 28.9 percent last month.

“Patients and providers might be reaching for the alternatives and generics that have recently hit the shelves, as the industry responds to widespread demand,” the report suggested regarding the uptick.

Kaleo re-launched Auvi-Q last month, which provides audio instructions designed to guide users through the administration process. Its list price is $4,500 for a two pack, but the firm launched a patient assistance program to drastically lower out-of-pocket costs.  

CVS is selling the generic Adrenaclick for a total of $10 thanks to a deal with the original manufacturer and a $100 discount coupon. These syringes are available at all of CVS’s stores.

Plus, insurers like Cigna curtailed their coverage plans to only include Mylan’s generic version of the EpiPen, which can impact prescription patterns too.

You can check out a chart from AthenaHealth’s report below.

Source: AthenaResearch


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50